Literature DB >> 17463082

Cyclophilin D inactivation protects axons in experimental autoimmune encephalomyelitis, an animal model of multiple sclerosis.

Michael Forte1, Bruce G Gold, Gail Marracci, Priya Chaudhary, Emy Basso, Dustin Johnsen, Xiaolin Yu, Jonathan Fowlkes, Micha Rahder, Katie Stem, Paolo Bernardi, Dennis Bourdette.   

Abstract

Multiple sclerosis (MS) is the leading cause of neurological disability in young adults, affecting some two million people worldwide. Traditionally, MS has been considered a chronic, inflammatory disorder of the central white matter in which ensuing demyelination results in physical disability [Frohman EM, Racke MK, Raine CS (2006) N Engl J Med 354:942-955]. More recently, MS has become increasingly viewed as a neurodegenerative disorder in which neuronal loss, axonal injury, and atrophy of the CNS lead to permanent neurological and clinical disability. Although axonal pathology and loss in MS has been recognized for >100 years, very little is known about the underlying molecular mechanisms. Progressive axonal loss in MS may stem from a cascade of ionic imbalances initiated by inflammation, leading to mitochondrial dysfunction and energetic deficits that result in mitochondrial and cellular Ca2+ overload. In a murine disease model, experimental autoimmune encephalomyelitis (EAE) mice lacking cyclophilin D (CyPD), a key regulator of the mitochondrial permeability transition pore (PTP), developed EAE, but unlike WT mice, they partially recovered. Examination of the spinal cords of CyPD-knockout mice revealed a striking preservation of axons, despite a similar extent of inflammation. Furthermore, neurons prepared from CyPD-knockout animals were resistant to reactive oxygen and nitrogen species thought to mediate axonal damage in EAE and MS, and brain mitochondria lacking CyPD sequestered substantially higher levels of Ca2+. Our results directly implicate pathological activation of the mitochondrial PTP in the axonal damage occurring during MS and identify CyPD, as well as the PTP, as a potential target for MS neuroprotective therapies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17463082      PMCID: PMC1857227          DOI: 10.1073/pnas.0702228104

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  47 in total

Review 1.  Mitochondrial transport of cations: channels, exchangers, and permeability transition.

Authors:  P Bernardi
Journal:  Physiol Rev       Date:  1999-10       Impact factor: 37.312

Review 2.  Mitochondria and calcium signaling.

Authors:  David G Nicholls
Journal:  Cell Calcium       Date:  2005 Sep-Oct       Impact factor: 6.817

Review 3.  Anti-inflammatory immunotherapy for multiple sclerosis/experimental autoimmune encephalomyelitis (EAE) disease.

Authors:  Jagat R Kanwar
Journal:  Curr Med Chem       Date:  2005       Impact factor: 4.530

4.  Clinical and magnetic resonance imaging changes correlate in a clinical trial monitoring cyclosporine therapy for multiple sclerosis. The MS Study Group.

Authors:  G J Zhao; D K Li; J S Wolinsky; R A Koopmans; W Mietlowski; W K Redekop; A Riddehough; K Cover; D W Paty
Journal:  J Neuroimaging       Date:  1997-01       Impact factor: 2.486

5.  Properties of the permeability transition pore in mitochondria devoid of Cyclophilin D.

Authors:  Emy Basso; Lisa Fante; Jonathan Fowlkes; Valeria Petronilli; Michael A Forte; Paolo Bernardi
Journal:  J Biol Chem       Date:  2005-03-25       Impact factor: 5.157

6.  Loss of cyclophilin D reveals a critical role for mitochondrial permeability transition in cell death.

Authors:  Christopher P Baines; Robert A Kaiser; Nicole H Purcell; N Scott Blair; Hanna Osinska; Michael A Hambleton; Eric W Brunskill; M Richard Sayen; Roberta A Gottlieb; Gerald W Dorn; Jeffrey Robbins; Jeffery D Molkentin
Journal:  Nature       Date:  2005-03-31       Impact factor: 49.962

7.  Cyclophilin D-dependent mitochondrial permeability transition regulates some necrotic but not apoptotic cell death.

Authors:  Takashi Nakagawa; Shigeomi Shimizu; Tetsuya Watanabe; Osamu Yamaguchi; Kinya Otsu; Hirotaka Yamagata; Hidenori Inohara; Takeshi Kubo; Yoshihide Tsujimoto
Journal:  Nature       Date:  2005-03-31       Impact factor: 49.962

Review 8.  Emerging therapies in multiple sclerosis.

Authors:  Rachel Farrell; Dominic Heaney; Gavin Giovannoni
Journal:  Expert Opin Emerg Drugs       Date:  2005-11       Impact factor: 4.191

Review 9.  General mechanisms of axonal damage and its prevention.

Authors:  Peter K Stys
Journal:  J Neurol Sci       Date:  2005-06-15       Impact factor: 3.181

10.  Cyclophilin D is a component of mitochondrial permeability transition and mediates neuronal cell death after focal cerebral ischemia.

Authors:  Anna C Schinzel; Osamu Takeuchi; Zhihong Huang; Jill K Fisher; Zhipeng Zhou; Jeffery Rubens; Claudio Hetz; Nika N Danial; Michael A Moskowitz; Stanley J Korsmeyer
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-15       Impact factor: 11.205

View more
  94 in total

1.  Genetic inactivation of the p66 isoform of ShcA is neuroprotective in a murine model of multiple sclerosis.

Authors:  Kimmy G Su; Costanza Savino; Gail Marracci; Priya Chaudhary; Xiaolin Yu; Brooke Morris; Danielle Galipeau; Marco Giorgio; Michael Forte; Dennis Bourdette
Journal:  Eur J Neurosci       Date:  2012-01-25       Impact factor: 3.386

2.  Deletion of mitochondrial anchoring protects dysmyelinating shiverer: implications for progressive MS.

Authors:  Dinesh C Joshi; Chuan-Li Zhang; Tien-Min Lin; Anchal Gusain; Melissa G Harris; Esther Tree; Yewin Yin; Connie Wu; Zu-Hang Sheng; Robert J Dempsey; Zsuzsanna Fabry; Shing Yan Chiu
Journal:  J Neurosci       Date:  2015-04-01       Impact factor: 6.167

3.  Cyclophilin D controls mitochondrial pore-dependent Ca(2+) exchange, metabolic flexibility, and propensity for heart failure in mice.

Authors:  John W Elrod; Renee Wong; Shikha Mishra; Ronald J Vagnozzi; Bhuvana Sakthievel; Sanjeewa A Goonasekera; Jason Karch; Scott Gabel; John Farber; Thomas Force; Joan Heller Brown; Elizabeth Murphy; Jeffery D Molkentin
Journal:  J Clin Invest       Date:  2010-09-20       Impact factor: 14.808

4.  Cyclophilin D and the mitochondrial permeability transition in kidney proximal tubules after hypoxic and ischemic injury.

Authors:  Jeong Soon Park; Ratna Pasupulati; Thorsten Feldkamp; Nancy F Roeser; Joel M Weinberg
Journal:  Am J Physiol Renal Physiol       Date:  2011-04-13

5.  Human coronavirus-induced neuronal programmed cell death is cyclophilin d dependent and potentially caspase dispensable.

Authors:  Dominique J Favreau; Mathieu Meessen-Pinard; Marc Desforges; Pierre J Talbot
Journal:  J Virol       Date:  2011-10-19       Impact factor: 5.103

Review 6.  Cyclophilin D in mitochondrial pathophysiology.

Authors:  Valentina Giorgio; Maria Eugenia Soriano; Emy Basso; Elena Bisetto; Giovanna Lippe; Michael A Forte; Paolo Bernardi
Journal:  Biochim Biophys Acta       Date:  2009-12-21

Review 7.  Review: Mitochondria and disease progression in multiple sclerosis.

Authors:  D Mahad; H Lassmann; D Turnbull
Journal:  Neuropathol Appl Neurobiol       Date:  2008-12       Impact factor: 8.090

8.  Role of cyclophilin D-dependent mitochondrial permeability transition in glutamate-induced calcium deregulation and excitotoxic neuronal death.

Authors:  Viacheslav Li; Tatiana Brustovetsky; Nickolay Brustovetsky
Journal:  Exp Neurol       Date:  2009-02-21       Impact factor: 5.330

9.  Lipoic acid reduces inflammation in a mouse focal cortical experimental autoimmune encephalomyelitis model.

Authors:  Priya Chaudhary; Gail Marracci; Danielle Galipeau; Edvinas Pocius; Brooke Morris; Dennis Bourdette
Journal:  J Neuroimmunol       Date:  2015-11-11       Impact factor: 3.478

Review 10.  Is multiple sclerosis a mitochondrial disease?

Authors:  Peizhong Mao; P Hemachandra Reddy
Journal:  Biochim Biophys Acta       Date:  2009-07-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.